Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819838) titled 'Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations' on Sept. 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Children's Oncology Group
Condition:
Recurrent Childhood Malignant Solid Neoplasm
Recurrent Childhood Neuroblastoma
Recurrent Childhood Rhabdomyosarcoma
Refractory Childhood Malignant Solid Neoplasm
Refractory Childhood Neuroblastoma
Refractory Childhood Rhabdomyosarcoma
Intervention:
Procedure: Biospecimen C...